anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND/OBJECTIVES: There is currently limited understanding of the intricate dynamics between fat and muscle mass and the potential effect of dietary patterns. This study aimed to investigate the effects of overall dietary patterns on four body composition phenotypes associated with central obesity and low muscle mass in the middle-aged and elderly population of Korea.
METHODS: We examined data from 6120 adults aged ≥ 50 years, collected during the 4th (2008-2009) and 5th (2010-2011) Korea National Health and Nutrition Examination Survey. Participants were classified into four groups according to their combined status of central obesity and low muscle mass: healthy control, central obesity, low muscle mass, and sarcopenic obesity. Using factor analysis on the twenty-two pre-defined food groups, we identified three distinct dietary patterns: the "Healthy dietary pattern", "Convenience-based dietary pattern", and "Alcohol and side dish pattern". Multivariate analysis included potential confounders such as age, sex, place of residence, marital status, educational level, occupation, household income, and physical activity level.
RESULTS: Higher scores in the "Healthy dietary pattern" were associated with lower odds of sarcopenic obesity (OR = 0.61, 95% CI = 0.40-0.92, p for trend = 0.018). For the "Convenience-based dietary pattern", individuals in the third tertile of the dietary pattern score showed a marginal association with low muscle mass (OR = 1.18, 95% CI = 0.99-1.41, p for trend = 0.056). The "Alcohol and side dish pattern" was linked to higher odds of central obesity (OR = 1.22, 95% CI = 1.03-1.44, p for trend = 0.016) and low muscle mass (OR = 1.21, 95% CI = 1.01-1.45, p for trend = 0.043).
CONCLUSIONS: The drinking practice of consuming foods high in saturated fats and salt alongside alcoholic drinks may negatively affect fat accumulation and muscle composition among older adults. Adopting a healthy eating pattern characterized by grains, vegetables, legumes, fruits, fish, and seaweed could be notably advantageous for promoting and maintaining healthy body composition and optimal skeletal muscle health.
BACKGROUND: Williams-Beuren syndrome (WBS) is a rare genetic disorder caused by hemizygous microdeletion of contiguous genes on chromosome 7q11.23. Although the phenotype features extensive heterogeneity in severity and performance, WBS is not considered to be a predisposing factor for cancer development. Currently, hematologic cancers, mainly Burkitt lymphoma, are rarely reported in patients with WBS. Here in, we report a unique case of T-cell acute lymphoblastic leukemia in a male child with WBS.
METHODS: This retrospective study analyzed the clinical data of this case receiving chemotherapy were analyzed. This is a retrospective study.
RESULTS: The patient, who exhibited a typical WBS phenotype and presented with hemorrhagic spots. Chromosomal genome-wide chip analysis (CMA) revealed abnormalities on chromosomes 7 and 9. The fusion gene STIL-TAL1 and mutations in BCL11B, NOTCH1, and USP7 have also been found and all been associated with the occurrence of T-cell leukemia. The patient responded well to the chemotherapy.
CONCLUSION: To the best of our knowledge, this is the first reported case of WBS in T-cell acute lymphoblastic leukemia. We want to emphasize that the occurrence of leukemia in this patient might be related to the loss of 7q11.23 and microdeletion of 9p21.3 (including 3 TSGs), but the relationship between WBS and malignancy remains unclear. Further studies are required to clarify the relationship between WBS and malignancy.
Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive FF/UMEC/VI (100mcg/62.5mcg/25mcg) via the ELLIPTA DPI and placebo via reservoir inhaler.
Community-based aquatic exercise program (Arthritis Foundation Aquatics Program). Two classes per week, 45-60 minutes in duration.
FIELD: medicine, urology. SUBSTANCE: the method deals with treating prostatic adenoma. To determine therapy type one should study volumetric rate of urination due to uroflowmetry. Then it is necessary to prescribe the intake of α 1  - adrenoblocking agent for 2 wk, for example, tamsulozine. Repeated uroflowmetry should be carried out. In case of higher value under testing after treating with α 1  - adrenoblocking agent it is necessary to continue medicinal therapy, in case of deterioration - one should conduct surgical treatment. EFFECT: shortened terms and improved quality of therapy. 2 cl
PURPOSE:To provide a sustained release tablet capable of effectively controlling the dissolution rate of drug component and enabling the use of a hydrophilic drug component or the increase of the concentration of the drug component without increasing the diameter of the tablet. CONSTITUTION:The objective tablet contains hydroxypropylmethylcellulose (HPMC) as a sustained release base component. The HPMC has a particle size distribution to pass at least 95wt.% of the HPMC through a 100 mesh sieve. The substitution degree of methoxyl group is 19-24wt.% and that of hydroxypropoxyl group is 4-12wt.%. The viscosity of 2% aqueous solution of the HPMC at 20 deg.C is preferably >=14,000cP. The content of the HPMC in the sustained release tablet is preferably 5-90wt.%.
A QDOT® 3.5-mm open-irrigated contact force-sensing RF ablation catheter (Biosense Webster, Inc., Irvine, CA, USA) will be used. Ablation of the anterior aspect of the pulmonary veins will be performed with high-power short-duration (50 W) with target ablation index =550. Ablation of the posterior wall of the pulmonary veins will be performed with vHPSD (90W).
Optic neuritis, papilledema, and cerebral blindness have been reported in patients receiving standard recommended doses of cisplatin. Improvement and/or total recovery usually occurs after discontinuing cisplatin. Steroids with or without mannitol have been used; however, efficacy has not been established.

Blurred vision and altered color perception have been reported after the use of regimens with higher doses of cisplatin or greater dose frequencies than recommended in the package insert. The altered color perception manifests as a loss of color discrimination, particularly in the blue-yellow axis. The only finding on funduscopic exam is irregular retinal pigmentation of the macular area.
Hair loss concerns over 42 % of the male population in the world. The key factors of that disorder are excessive degradation of testosterone into dihydrotestosterone and lack of nutrients essential in hair follicles. Treatment by local application show little cutaneous absorption, food supplements have no effect on the conversion of testosterone and orally administered medicines exhibit high toxicity. Said treatments have very limited efficacy. The invention concerns the use of plant extract combinations inhibiting 5-alpha reductase acting synergistically and preventing conversion of testosterone into dihydrotestosterone. Said combinations are useful for preparing compositions for local application for treating hair loss. Their combination with an absorption promoter enables to transport the active principles specifically in the hair follicles without producing any secondary effects. The use of food supplements containing amino acids, vitamins and minerals further enhance the effect of compositions for local application. The inventive plant extract combinations can be used as cosmetic or pharmaceutical product for treating hair loss and androgenic alopecia.
Stroke is an acute injury of the central nervous system caused by the disorders of cerebral blood circulation, which has become one of the major causes of disability and death. Hemorrhage, particularly subarachnoid hemorrhage (SAH), is one of the poorest prognostic factors in stroke, which is related to the thrombolytic therapy, and has been considered very dangerous. In this context, the MR angiography with high sensitivity and resolution has been developed based on biocompatible paramagnetic ultrasmall NaGdF4 nanoprobes. Owing to the appropriate hydrodynamic diameter, the nanoprobe can be confined inside the blood vessels and it only extravasates at the vascular injury site when the bleeding occurs. Relying on this property, the three-dimensional (3D) anatomic structures of artery occlusion of stroke rat can be precisely visualized; reperfusion-related SAH has been successfully visualized and identified. Benefiting from the long blood half-life of the nanoprobe, the observation window of MR angiography can last for the whole period of reperfusion, thereby monitoring the probable SAH in real time during thrombolytic therapy. More importantly, through reconstruction of multiparametric MRI, the arterial occlusion, cerebral ischemic region, and SAH can be simultaneously visualized in vivo in a 3D manner for the first time. Therefore, the current study provides a novel approach for both noninvasive 3D vascular visualization and hemorrhage alert, which possesses great prospects for clinical translation.
PURPOSE:To provide a drug carrier having organ directiveness, esp. digestive organ directiveness, having its selective residence possibility inside the upper digestive organs carrying a drug thereon, consisting of a polymeric compound having both carboxyl group and cyclodextrin residue at the side chain. CONSTITUTION:The carrier consisting of a polymeric compound pref. 1000-10000000 in the molecular weight of the main chain, having at the side chain 5-65wt.%, based on the polymeric compound, of carboxyl group and 1-90wt.%, based on the polymeric compound, of cyclodextrin residue (e.g. prepared by ester-linking of a cyclodextrin to an unsaturated carboxylic acid homopolymer or copolymer). This carrier can be obtained by activating the carboxylic acid segment of a polymer bearing carboxyl group at the side chain with a carbonyldiimidazole followed by reaction with a cyclodextrin.
A powder for use in a cosmetic is provided. Said powder is highly water-repellent; feels smooth, light, and moisturizing; and adheres well to the skin. The use of said powder in a cosmetic provides said cosmetic with a pleasant feel; excellent, long-lasting efficacy; and superb temporal stability. The present invention is a powder for use in a cosmetic, said powder having been surface-treated by a silicone gel. Surface-treating said powder with a silicone gel makes the powder highly water-repellent; produces a smooth, light feel; provides the moisturizing feel characteristic of silicone gels; and makes the powder adhere well to the skin. This powder is preferably either an inorganic powder, an organic powder, or a compound powder consisting of an inorganic powder and an organic powder. Furthermore, the aforementioned silicone gel is preferably obtained by performing a hydrolytic condensation reaction on the diorganopolysiloxane represented by formula (1), both ends of which are reactive, and an organopolysiloxane cross-linker containing one or both of the following: the silane coupling agent represented by formula (2), which has two or more hydrolyzable groups per molecule; and the reactive organopolysiloxane represented by formula (3).
An approach is described herein for providing feedback to the participants of a communication session. The approach entails automatically collecting cue information that characterizes, at least in part, the communication behavior that is exhibited during the communication session. The approach then generates signal information based on the cue information. In one case, the signal information conveys the empathy that is exhibited during the communication session. In one case, the signal information may have an affiliation dimension and a control dimension. Any participant can use the signal information during and/or after the communication session to gain awareness of his or her communication style, and to potentially modify his or behavior in response thereto.
Avascular necrosis of the femoral head (ANFH) is a progressive, multifactorial, and challenging clinical condition that often leads to hip dysfunction and deterioration. The pathogenesis of ANFH is complex, and there is no foolproof treatment strategy. Although some pharmacologic and surgical treatments have been shown to improve ANFH, the associated side effects and poor prognosis are of concern. Therefore, there is an urgent need to explore therapeutic interventions with superior efficacy and safety to improve the quality of life of patients with ANFH. Salvia miltiorrhiza (SM), a traditional Chinese medicine with a long history, is widely used for the treatment of cardiovascular and musculoskeletal diseases due to its multiple pharmacological activities. However, the molecular mechanism of SM for the treatment of ANFH is still unclear. Therefore, this study aimed to explore the potential targets and mechanisms of SM for the treatment of ANFH using network pharmacology and molecular modeling techniques. By searching multiple databases, we screened 52 compounds and 42 common targets involved in ANFH therapy and identified dan-shexinkum d, cryptotanshinone, tanshinone iia, and dihydrotanshinlactone as key compounds. Based on the protein-protein interaction (PPI) network, TP53, AKT1, EGFR, STAT3, BCL2, IL6, and TNF were identified as core targets. Subsequent enrichment analysis revealed that these targets were mainly enriched in the AGE-RAGE, IL-17, and TNF pathways, which were mainly associated with inflammatory responses, apoptosis, and oxidative stress. In addition, molecular docking and 100 nanoseconds molecular dynamics (MD) simulations showed that the bioactive compounds of SM had excellent affinity and binding strength to the core targets. Among them, dan-shexinkum d possessed the lowest binding free energy (-215.874 kcal/mol and - 140.277 kcal/mol, respectively) for AKT1 and EGFR. These results demonstrated the multi-component, multi-target, and multi-pathway intervention mechanism of SM in the treatment of ANFH, which provided theoretical basis and clues for further experimental validation and development of anti-ANFH drugs.
MIE will be given as prescribed by physician responsible at the intermediate care unit, typically every 4 hours. MIE will be administered with standard settings of insufflation 20 cm H2O and exsufflation 20 cm H2O, with possible individual changes from 10/-10 H2O up to 40/-40 H2O, and oxygen flow up to 15 l/min. The standard settings will be set to five cycles of 2 seconds insufflation, 3 seconds exsufflation with a three second pause between each cycle. Every treatment session consists of five rounds of five cycles, in all 25 insufflation/exsufflation, with time between each cycle of 30 seconds, meant used for suction.
Migraine is a common chronic neurological disorder characterized by recurrent disabling episodes of moderate to severe headache accompanied by nausea, vomiting, photophobia, and phonophobia. Acute pharmacologic therapy for migraine aims to terminate the attack or reduce its severity. Analgesics are commonly used or, if these are ineffective, triptans. Since triptans are contraindicated in patients with coronary artery disease, uncontrolled hypertension, and cerebrovascular disease alternative medications are required for patients where simple analgesics do not work. COL-144 has no vasoconstrictor activity at clinically relevant concentrations and might meet this need. COL-144 was effective when given intravenously in a placebo-controlled dose-ranging study. This study investigates which dose of oral COL-144 is effective in the in acute treatment of migraine headache.
PROBLEM TO BE SOLVED: To easily obtain a candy and beverage containing crystal kestose, having hydroscopicity equivalent to that in the case of using sugar and the functionality of fructooligosaccharide, and effective for intake calorie reduction and health promotion. SOLUTION: This product contains crystal kestose as a component of fructooligosaccharides. The purity of the crystal kestose is pref. >=94%. It is preferable that the amount of the crystal kestose to be formulated is 1-99wt.% of the total amounts of the materials to be used for this product. To produce the objective product, processes, apparatuses, etc., similar to those for conventional tablet candies and powder beverages using sugar car be applied. Low- caloric sweetener(s) hard to develop dental caries such as aspartame or maltitol may be used in combination with the crystal kestose.
Patients receive afatinib dimaleate as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To obtain an enteric pharmaceutical preparation having an anti- adhesion layer, having acid resistance and excellent in anti-adhesion effects according to the solventless coating in a short time without requiring drying. SOLUTION: This enteric pharmaceutical preparation is obtained by spraying and coating a solid medicine with a fine powdery enteric coating agent while spraying a solventless liquid plasticizer or waxes thereon or spraying and coating the solid medicine with the fine powdery enteric coating agent while heating solventless and powdery or pelletlike waxes at a temperature above the melting point thereof and spraying the heated waxes thereon and then spraying and coating the outer layer thereof with a solventless anti-adhesion layer (an anti- adhesion agent for the coated pharmaceutical preparation) in an amount of 2-10wt.% based on the solid medicine. Tale, Carplex (R) (SiO2 ), magnesiun stearate. beeswax, paraffin, etc., are cited as the anti-adhesion layer. The average particle diameter of the fine powdery enteric coating agent is preferably <=10μm.  The weight ratio of the plasticizer or waxes:enteric coating agent is about (2:8) to (8:2).
The present invention relates to medicine for treating coronary disease and angina pectoris, and a preparation method for the medicine. The medicine is composed of the following raw materials by weight portions: 4 to 60 portions of pueraria root total flavonoid, 1 to 30 portions of hawkthorn extract, 0.4 to 10 portions of gynostemma pentaphylla total glycosides, 5 to 100 portions of soybean oil, 0.1 to 3 portions of beeswax, 0.4 to 10 portions of hydrogenated palm oil, 0.2 to 5 portions of soybean phospholipid, 0.01 to 0.5 portion of methyl silicone oil, 8 to 150 portions of gelatin, 3 to 80 portions of glycerin, 8 to 150 portions of distilled water and 0.01 to 0.8 portion of ethylparaben. The preparation method comprises: preparing a proper amount of distilled water, gelatin, glycerin and ethylparaben into a capsule solution; adding a definite amount of beeswax and hydrogenated palm oil into soybean oil; heating the beeswax, the hydrogenated palm oil and the soybean oil, so the beeswax and the hydrogenated palm oil are completely dissolved in the soybean oil; cooling; adding soybean phospholipid; stirring sufficiently so as to achieve uniformity; gradually adding the medicinal powder of gynostemma pentaphylla total glycosides, hawkthorn extract and pueraria root total flavonoid, and the medicinal powder is sieved by 60 meshes; stirring sufficiently so that the medicinal powder can be blended evenly; milling the medicinal powder twice by a colloid mill; adding methyl silicone oil; placing still; pumping vacuum. When bubbles in medicinal liquor are basically removed, the medicinal liquor is used for standby. The molten capsule solution is used for pressing pills. 580 mg of medicinal liquor is pressed into each pill. The thickness of a capsule skin is about 0.85 to 0.95mm. The pills are formed by a pressing method.
Ultrasound guidance will be used with a high- frequency linear transducer.After the joint has been identified, the researcher will ask the patient to hold mouth in a neutral position. Masseter, temporalis, medial and lateral pterygoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection. Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, 0.5 ml of normal saline will be injected (to decrease the impedance of the tissues), the electrode will be inserted, and extra-articular PRF will be performed during 4 minutes at 42 degrees Celsius for each muscle. At the end of each muscle treatment, 1 ml of local anesthetic (lidocaine 1%) will be injected through the RF needle, and the needle will be removed.
A topical medication garment, a system and a method provide topical medication. An impermeable garment may allow the topical medication to maintain contact with the skin of the user. The garment may prevent the topical medication from absorption into clothing or the undergarment itself. The entirety of the garment may be made from an impermeable material or a portion of the garment may be made from an impermeable material. An impermeable liner may be attached to and/or may be connected to an interior surface of the garment. The garment may have legging portions that reside on the upper thighs of the user when the garment is worn. The legging portions may secure the position of the garment on the user and providing coverage of topical medication applied to the crotch area and upper thighs. The garment may have a structure that resembles a t-shirt.
PURPOSE:To obtain an artificial carrier having a uniform quality at all times by adding an anionic macromolecular electrolyte to gelatin and metaphosphate. CONSTITUTION:An anionic macromolecular electrolyte is used instead of a water-soluble polysaccharide, in addition to gelatin and metaphosphate, as an artificial carrier. As for the anionic macromolecular electrolyte, a macromolecular acid salt, more concretely, a polyacrylic acid salt, a polymethacrylic acid salt, a polystyrene sulfonic acid salt, a polyethylene sulfonic acid salt, a polyvinyl sulfate or the like is used, and among them, the polyacrylic acid salt is suitable. Among these anionic macromolecular electrolytes, those having an average molecular weight of 1,000 to 1,000,000 can be used, and preferably those having an average molecular weight of 2,000 to 80,000 are used. Herein the salt is an alkali metal salt, concrete examples of which are sodium, potassium, etc. By adding this anionic macromolecular electrolyte to the gelatin and the metaphosphate, an artificial carrier having uniform properties at all times can be obtained.
The invention belongs to the technical field of medicine fluid distribution. In contrast to the injection mode, external drug administration devices often store more drug and are applied in batches on multiple occasions. The external drug devices often have long service periods and relatively poor storage conditions, which put higher requirements on the stability of the drugs therein, and the selection of the drug excipients and the compatibility with the packing materials are usually key factors for the selection. Where the device is used multiple times or requires only a small amount of liquid to load the drug itself, the dose delivery is insufficient and/or varies widely, usually with degradation of the active ingredient being a first indication. Although in most cases the stability of the medicament is not sufficient as is generally known, the therapeutic effect is deteriorated by degradation of the active ingredient. However, this also limits the thinking of those skilled in the art. The present invention has been made in an intensive study to find out another cause of instability of the therapeutic effect accompanying the use of the drug, and to provide a novel fluid dispenser for a drug based on the finding.